风险-效益评估的舒必利治疗精神分裂症。

文章的细节

引用

复制到剪贴板

布拉万年代,毛里MC Bitetto, Rudelli R, Invernizzi G

风险-效益评估的舒必利治疗精神分裂症。

药物Saf。1996年5月,14 (5):288 - 98。doi: 10.2165 / 00002018-199614050-00003。

PubMed ID

8800626 (在PubMed

]

文摘

舒必利是一种取代苯甲酰胺与多巴胺受体选择性行动D2-like家庭,和临床药理数据表明,它可以被认为是一个非典型抗精神病药物。舒必利穿透血脑屏障不因为其脂溶性低。主要原型排泄尿液中,积累的药物可能发生在患者肾脏功能障碍和可能在老年患者肾小球滤过率下降。在低剂量(50到150毫克/天),舒必利产生放纵和抗抑郁效果,这可能是有关其行动D2突触前受体,从而促进多巴胺能神经传递。数据已经证实舒必利的功效在急性或慢性精神分裂症患者在短期和长期治疗,但长远来看,安慰剂对照试验仍然缺乏。它仍然怀疑舒必利比典型的抗精神病药物更有效治疗阴性症状。临床研究的数据有争议;大多数作者表明,舒必利产生更好的回收率从负面比阳性症状在低剂量,但它显示了一个类似的功效在正面和负面症状在较高剂量。舒必利的安全性是类似于典型的抗精神病药物,虽然副作用的频率似乎是全球低。出现锥体束外的反应通常是温和的。 Autonomic effects occur less frequently with sulpiride than with typical antipsychotics, showing no clinically relevant influence on cardiovascular parameters and, on the whole, good tolerability in elderly patients. Sulpiride is known to induce prolactin elevation in both serum and CSF, which may be associated with impotence in men and diminished gonadal function in women; these effects appear to be dosage-dependent. Sulpiride can be considered to be an atypical antipsychotic, considering its action on negative, defective symptoms, its partial activity against positive symptoms, and its low incidence of extrapyramidal adverse effects. Sulpiride could find its specific therapeutic role in elderly patients with schizophrenia, as it shows a good margin of safety between therapeutic dosages and toxic concentrations.

DrugBank数据引用了这篇文章

药物

舒必利